Close Menu

UPenn

The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.

Clinicians and genetic counselors are coming up with triage strategies for cancer cases in which medically actionable germline mutations are suspected.

The device, which will be tested in collaboration with a Panamanian research institute, will run 40-minute tests without the need for electricity.

UPenn will establish the Coordinating Center for Genetics and Genomics of Alzheimer's Disease in collaboration with five other institutions.

The UPenn-led study proposal calls for editing three genes in autologous T cells with CRISPR and includes preliminary data for on- and off-target editing.

A safety panel is to review a proposal next week to use CRISPR as part of a cancer treatment, Technology Review reports.

A member of the committee issuing a blunt report on the inadequacy of biomarker-based testing speaks about what the next Secretary of HHS needs to do.

The university formed the new venture in collaboration with Blueprint Bio and Emerald Logic in order to discover biomarkers for personalized medicine.

Researchers saw an 'incremental clinical benefit' from analyzing 180 genes in the exomes of hundreds of individuals from families affected by breast or ovarian cancer.

The group compared results of 304 cancer specimens tested by both NGS and one or more single-gene tests, showing almost complete concordance.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.